- 1 Prevalence of multimorbidity combinations and their association with
- 2 medical costs and poor health: a population-based study of U.S.
- 3 adults
- 5 Nicholas K. Schiltz, PhD¹
- ¹Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio,
- 7 USA

12

16

- 8 ²Department of Population & Quantitative Health Sciences, Case Western Reserve University
- 9 School of Medicine, Cleveland, Ohio, USA
- 10 ³Center for Community Health Integration, Case Western Reserve University School of
- 11 Medicine, Cleveland, Ohio, USA
- 13 * Correspondence:
- 14 Nicholas K. Schiltz, PhD
- 15 nks8@case.edu
- 17 Keywords: Multimorbidity, Comorbidity, Multiple Chronic Conditions, Chronic Disease,
- 18 Practice Guidelines as Topic, Health status, Healthcare economics, Epidemiology

ABSTRACT

- 21 BACKGROUND: Multimorbidity is common, but the prevalence and burden of the specific
- 22 combinations of coexisting disease has not been systematically examined in the general U.S.
- 23 adult population.

20

- 24 **OBJECTIVE**: To identify and estimate the burden of highly prevalent combinations of chronic
- conditions that are treated among one million or more adults in the United States.
- 26 **METHODS**: Cross-sectional analysis of U.S. households in the Medical Expenditure Panel
- 27 Survey (MEPS), 2016–2019, a large nationally-representative sample of the community-
- dwelling population. Association rule mining was used to identify the most common
- combinations of 20 chronic conditions that have high relevance, impact, and prevalence in
- 30 primary care. The main measures and outcomes were annual treated prevalence, total medical
- 31 expenditures, and perceived poor health. Logistic regression was used to calculate adjusted
- 32 odds ratios and 95% confidence intervals.
- 33 **RESULTS**: Frequent pattern mining yielded 223 unique combinations of chronic disease,
- including 74 two-way (dyad), 115 three-way (triad), and 34 four-way combinations that are
- 35 treated in one million or more U.S. adults. Hypertension-hyperlipidemia was the most common
- 36 two-way combination occurring in 30.8 million adults. The combination of diabetes-arthritis-
- 37 cardiovascular disease was associated with the highest median annual medical expenditures
- 38 (\$23,850, [Interquartile range: \$11,593 \$44,616]), and the combination of diabetes-arthritis-
- 39 asthma/COPD} had the highest age-race-sex adjusted odds ratio of poor self-rated health
- 40 (adjusted odd ratio: 6.9, [95%CI: 5.4 8.8]).
- 41 **CONCLUSION**: This study demonstrates that many multimorbidity combinations are highly
- 42 prevalent among U.S. adults, yet most research and practice-quidelines remain single disease
- 43 focused. Highly prevalent and burdensome multimorbidity combinations could be prioritized for
- 44 evidence-based research on optimal prevention and treatment strategies.

INTRODUCTION

- 47 An estimated 42% percent of American adults 18 and older suffer from multiple chronic
- 48 conditions (i.e. multimorbidity). Persons with multimorbidity have higher mortality rates, lower
- 49 health-related quality life, increased healthcare use, and are at higher risk for many poor health
- 50 outcome events including adverse drug events.^{2–6}
- Despite the high frequency of multimorbidity in the population, most clinical practice guidelines,
- and the evidence they are based upon are single disease focused. Adhering to multiple,
- 53 sometimes conflicting, guidelines for multiple individual diseases is burdensome⁷ and conveys
- considerable risk to the patient in terms of drug-drug or drug-disease interactions.^{8,9} The overall
- optimal treatment plan for a given patient with multimorbidity is unlikely to be the linear
- combination of the best treatment for each individual condition.^{9,10} There is a clear need to
- 57 develop guidelines, care management plans, and patient education programs that meet the
- 58 needs of patients with multimorbidity. Understanding which conditions most commonly coexist
- 59 together and their impact on outcomes is a critical first step to establish research priorities for
- building the evidence-base necessary to achieve this.
- 61 Understanding the rate that disease coexist or cluster together at higher-than-expected rates,
- 62 may also provide clues about the etiology between two or more conditions. For example,
- 63 inflammation has been shown to be a mechanism for numerous conditions including cancer,
- 64 cardiovascular disease, chronic kidney disease, and diabetes. 11 Damage caused by vascular
- diseases may be a cause of Alzheimer's Disease and other dementias. ¹² Understanding these
- 66 shared risk factors and pathways could lead to the development of medications or behavioral
- 67 interventions that target more than one condition simultaneously, hence reducing polypharmacy
- and treatment burden in this population.
- While numerous data exist on the prevalence of single chronic conditions^{1,13}, much less is
- 70 known about the prevalence of specific combinations of multimorbidity. Most prevalence studies
- of multimorbidity are based on counts of conditions. ^{14,15} However, measuring the impact of
- 72 multimorbidity based on counts of conditions or weighted scores may miss important
- heterogeneity, because the specific combinations of chronic disease matter in terms of health
- outcomes¹⁶ including mortality and poor health,⁵ activity of daily living and instrumental activity
- of daily living limitations, ^{17,18} cost and utilization, ⁶ and quality of care. ¹⁹
- 76 Studies that have examined the prevalence of specific combinations of multimorbidity in the US
- have been mostly limited to dyad and triad combinations, ^{20–23} a small number of conditions, ^{17,24}
- 78 conducted in a specific sub-populations²¹ or geographic areas,²⁵ or limited to older adults.^{24,26}
- 79 The prevalence of specific multimorbidity combinations of the general community-dwelling adult
- 80 population has not been established comprehensively in the United States.
- 81 The goal of this study was to fill this knowledge gap and identify and rank the most frequent
- 82 multiway (two-way, three-way, four-way, etc...) combinations of multimorbidity treated among
- 83 adults in the United States. An innovative machine learning algorithm –association rule mining –
- was used to identify all combinations of multimorbidity occurring in one million or more U.S.

- 85 adults. The association with average and median per capita direct medical expenditures and
- 86 perceived fair or poor health status was also examined, to identify combinations associated with
- 87 the most burden.

89

106

110

METHODS

Design, Setting, and Participants

- 90 This study was a cross-sectional analysis of the 2016 2019 Medical Expenditure Panel Survey
- 91 Household Component (MEPS). The MEPS is a large-scale panel survey of a nationally
- 92 representative sample of households in the United States and is administered by the Agency for
- 93 Healthcare Research and Quality (AHRQ).²⁷ The MEPS collects data at the person-level on
- 94 numerous topics including medical expenditures, utilization, medical conditions, health status,
- 95 and demographics. Interviews are conducted in-person using computer-assisted personal
- 96 interview (CAPI) technology. The MEPS is designed in a way that it can be used for both
- 97 longitudinal analysis over a two-year period, and cross-sectional analysis to obtain annual
- 98 estimates in a single year, 28 or pooled across multiple years. 29 This study uses cross-sectional
- 99 methods and weights as the main goal was to produce national estimates of prevalence. The
- 100 2016 2019 data was chosen as these are the most recent currently available data and earlier
- 101 years used ICD-9-CM coding for medical conditions. Multiple years of data were pooled
- together to provide a larger sample size as some combinations will occur in less than 1% of the
- total study population.²⁹ This study included all adults age 18 and older with non-zero weights.
- 104 Subjects with missing data on self-reported health or expenditures were excluded (n≤10). The
- final unweighted sample was 89,947 adults (Supplementary Figure 1).

Ethics Statement

- The MEPS data used in this study is publicly available and de-identified. The Case Western
- 108 Reserve University Institutional Review Board reviewed the protocol for this study and deemed
- 109 it to be exempt under U.S. federal law.

Measures

- Health conditions were self-reported through open-ended questions about conditions reported to
- be treated with prescription medications or associated with health care utilization. The
- respondents verbatim text responses were coded according to the International Classification of
- 114 Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Treatment of these conditions
- may have been received through inpatient stays, outpatient or office-based visits, emergency
- department visits, home health care, or prescribed medications. Chronic conditions were then
- 117 classified into one of 20 chronic conditions used in recent studies of multimorbidity, because of
- their high relevance, impact, and prevalence among primary care clientele. ^{31–33} A list of each
- 119 chronic condition categories and corresponding ICD-10-CM codes is included in the appendix
- 120 (Supplementary Table 1).

- Perceived health was assessed by asking respondents to rate their health as excellent (1), very
- 122 good (2), good (3), fair (4), or poor (5). The variable was dichotomized into two values: a
- response of excellent, very good, or good was categorized as good perceived health, while a
- response of fair or poor was categorized as poor perceived health.
- Medical expenditures were defined as the sum of direct payments for care provided during the
- 126 year, including out-of-pocket payments and payments by private insurance, Medicaid, Medicare,
- and other sources. Expenditure data were collected in the MEPS through both self-report and
- through data collected from the respondents' physicians, hospitals, and pharmacies, when
- available. The MEPS provides imputed values when data are missing or payments are made
- under capitated plans.³⁴ Total expenditures were adjusted for annual inflation and are reported
- in terms of 2019 dollars using the Personal Consumption Expenditure Health Price Index from
- the Bureau of Economic Analysis.³⁵ Out-of-pocket expenditures were adjusted for inflation using
- the Consumer Price indices for medical care (CPI–M).³⁵

Statistical Analysis:

- The main analytic techniques in this study were association rule mining and frequent pattern
- mining.³⁶ In brief, association rule mining can be thought of as a two-step process. In the first
- step (frequent pattern mining) all combinations of items with a minimum support (i.e. prevalence
- in the study population) are discovered. In the second step, "association rules" of the form X =
- Y are created, where X is one or more items (chronic conditions in this study) and Y is a single-
- item consequent (poor health or medical expenditures in our study) that X is associated with.
- The method was applied here by treating each subject in the study data as the "transaction,"
- and each chronic condition as the "items" to find the most frequently coexisting combinations
- out of the 1,048,576 (2²⁰) possible combinations of 20 conditions. The minimum support
- 144 (prevalence) threshold was set at 0.20% for the initial pass, and then after applying survey
- weights, any combinations with a point estimate of less than one million adults (~0.40% of the
- 146 U.S. adult population) was dropped.
- 147 The MEPS uses a complex stratified random sampling design. Design-based survey methods
- 148 (i.e. Taylor series estimation) were used to account for stratification and clustering effects when
- estimating variances.³⁷ Person-level weights in each year were divided by four (number of total
- 150 years of data) and applied to get the annualized estimated number and percent of persons with
- a disease combination and 95% confidence interval.²⁸ Likewise, the median and average annual
- per capita medical expenditures, per capita out-of-pocket expenses, and percent self-reporting
- poor health status was calculated for each combination after applying weights.
- 154 Combinations of conditions and corresponding prevalence estimates represent "at least", rather
- than "exactly." For example, people with hypertension-hyperlipidemia-diabetes would be a
- subset of the people with hypertension-diabetes.
- 157 For each combination, we calculated the observed-to-expected prevalence ratio (also known as
- lift), which is the observed prevalence of the combination divided by the expected prevalence

159 given all single diseases in the combination are independent of each other. Lift significantly

- greater (or lower) than 1 indicates the coexistence of diseases is unlikely due to chance alone.
- To identify specific combinations associated with the highest average cost and perceived poor
- health burden, we filtered out combinations that were redundant in that they offered little new
- information on the outcome measure over a more parsimonious (i.e. superset) combination,
- using a minimum improvement criteria of 10%. 38,39
- 165 Survey-weighted logistic regression was used to estimate the age-race-sex adjusted odds ratio
- of poor health status for each disease combination, account for clustering and stratification.
- 167 Adjustment variables were age as a continuous variable with splines, race (Hispanic, non-
- Hispanic white, non-Hispanic black, non-Hispanic Asian, and other), and sex. Subgroup
- analysis was performed by sex as a secondary analysis.
- 170 Data pre-processing was performed using SAS version 9.4 for Windows. The analysis was
- 171 conducted using R version 4.1.0, RStudio (v. 1.4.1717), and R packages: arules (v. 1.6-8) and
- 172 survey (v. 4.1-1).40,41

RESULTS

- 174 The total weighted study population was 249.2 million adults age 18 and older, with 82.0 million
- 175 (32.9%) reporting receiving treatment for two or more conditions (Table 1) in a single year. 51.7
- million (20.7%) adults have three or more conditions, and 30.6 million (12.3%) have 4 or more
- 177 conditions. A dose response increase is evident between number of chronic conditions and the
- 178 percentage reporting poor perceived health and average annual medical expenditures. The
- prevalence of multimorbidity is highest in those ages 65 and older (73.0% or 38.0 million
- people), followed by age 40 to 64 (35% or 36.4 million people), and 18-39 (7.9% or 7.5 million).
- 181 Frequent pattern mining yielded 223 unique combinations of chronic disease, including 74 two-
- way, 115 three-way, and 34 four-way combinations that affect one million or more of the
- weighted study population. There are eight combinations that affect 10 million or more adults,
- 32 combinations that affect 5 million or more adults, and 129 that affect 2 million or more adults
- per year. There were not any five-way or higher combinations that met the minimum prevalence
- threshold. The full table is included in the supplementary material (Supplementary Table 2).
- Figure 1 shows the most prevalent combinations along with their associated total medical
- 188 expenditures (in billions of U.S. Dollars) and percent of the population reporting poor perceived
- health. An estimated 30.8 million people (12.4%, 95%CI: 12.0 12.8%) of the U.S. adult
- 190 population are treated for hypertension and hyperlipidemia the most common combination
- 191 (Table 2). An estimated 11.5 million people (4.6%, 95%CI: 4.4% 4.9%) have hypertension,
- 192 hyperlipidemia, and diabetes the most common 3-way combination, and fifth most common
- 193 combination overall. Hypertension, hyperlipidemia, musculoskeletal disorder, diabetes and
- arthritis was the most common 5-way combination (1.1%, 95%CI: 1.0% 1.2%). Combinations
- including hypertension and/or hyperlipidemia plus another condition comprise the majority of the

196 most prevalent combinations. An alternate version of the analysis excluding hypertension and

- hyperlipidemia is included in the supplement (Supplementary Figure 2).
- 198 All 223 combinations identified as highly prevalent had O/E ratios (and 95% confidence
- intervals) greater than 1, indicating the coexistence of these two conditions is unlikely due to
- 200 chance alone. The combination of hypertension, hyperlipidemia, diabetes, and cardiovascular
- disease had the highest observed-to-expected ratio of 38.6 (36.4 40.9). Cardiovascular
- disease and heart failure had the highest O/E of 7.4 (95% CI: 6.8 8.2%) for dyad combinations
- and hypertension, cardiovascular disease, and diabetes had the highest O/E of 11.4 (10.8 -
- 204 12.0) for triad conditions.

197

- Figure 2 shows specific combinations of multimorbidity that ranked in either the top 20 in terms
- of average medical expenditures or perceived poor health. A total of 28 combinations met either
- criteria, and 12 met both. The combination of heart failure and cardiovascular disease had the
- 208 highest average annual medical expenditures per capita (\$33,451, 95%CI: \$29,034 \$ 37,868).
- 209 This was 2.4 times higher than the average for having any two or more chronic conditions
- 210 (\$13,907). Average expenditures were higher than median expenditures across the board,
- indicating the right-skewed nature of expenditures. The combination of diabetes, asthma/COPD,
- and arthritis was most associated with perceived poor health status with an adjusted odds ratio
- of 6.9 (5.4 8.8) (Figure 2). The 62.9% reporting poor health was 2.1 times higher than the
- average percent reporting poor health among those with any three or more chronic conditions.
- 215 Supplementary Table 2 provide additional details on the out-of-pocket expenses associated with
- each combination, and Supplemental Figure 3 shows combinations with the highest average
- 217 out-of-pocket expenditures.
- The top ten combinations among male and female adults in the study population is shown in
- 219 Figure 3. Hypertension and hyperlipidemia was the top combination for both, but after that the
- results diverge. Hypertension and diabetes was 2nd for males, but 4th for females. Hypertension
- and chronic musculoskeletal conditions were 2nd for females, but 4th for males. Combinations
- with urinary problems appeared twice in the top ten ranking for males, but not for females.
- 223 Combinations with arthritis, thyroid disorders, stomach problems, and asthma/COPD appeared
- in the top ten for females but not males.

DISCUSSION

- This study combined data mining with survey epidemiology to comprehensively identify and
- 227 estimate the treatment prevalence of the most frequent combinations of multimorbidity in the
- 228 United States. This analysis showed that certain multimorbidity combinations of disease are not
- 229 idiosyncratic, but actually quite common in the US, occurring in one million or more adults.
- 230 This paper adds several new contributions to the literature. First, we provide important public
- 231 health data on the prevalence and associated outcomes of specific multimorbidity combinations.
- While it was not surprising to find hypertension and hyperlipidemia as the top combination, a
- fact that is well-established, 42 the approximate ranking and estimated prevalence of many other
- 234 combinations farther down the list was previously unknown. Second, this study provides data on

observed-to-expected prevalence ratio for each combination. Disease with high ratios likely share risk factors or have common pathways for disease, which could spur hypotheses for future research. Finally, we identify combinations with the highest burden in terms of total

expenditures and perceived poor health. These combinations could be priority targets for future

prevention or treatment interventions targeted toward multimorbidity patients.

Despite the high prevalence of these disease combinations, most evidence-based practice guidelines are single-disease focused. This relegates managing people with multimorbidity, who represent the majority of people presenting for primary care, to the "art", rather than the science of medicine, and has led to largely untargeted global interventions that show limited or no effect in clinical trials. While general approaches for complex patients exist including geriatric care teams, the Age-Friendly Health Systems 4M model of care, and deprescribing guidelines (e.g. Beers Criteria and STOPP/START), significant evidence gaps remain especially when it comes to specific guidelines for managing patients with specific combinations of conditions. For some conditions, multimorbidity may be the norm. For example, this study showed that 45 million adults are treated for hyperlipidemia, and of those approximately two-thirds are treated for hypertension as well. This means it is more common for a patient to be treated for high cholesterol plus another condition, than just managing cholesterol alone.

The highly prevalent combinations identified in this study could be prioritized for future evidence-based research. Some combinations show the possibility that a single medication could target multiple diseases thus reducing the polypharmacy. For example, a low-dose antidepressant for anxiety, can also treat pain from arthritis or diabetic neuropathy. Other common combinations show the potential of physical activity, diet, and tobacco cessation interventions to positively affect multiple conditions and reduce medication burden.

This was, to the author's knowledge, the most comprehensive, population-based study in the U.S. on the prevalence and associated impact of multimorbidity combinations in terms of the number of conditions, the examination of higher-order combinations (e.g. 4-way or deeper), and the broadness of the study population. Ward and Schiller examined common dyad and triad combinations of ten conditions using the National Health Interview Survey.²³ The most common dyad condition was hypertension-arthritis and 26% of adults had multimorbidity. A similar more recent study using 2018 NHIS data estimated that 27.2% of U.S. adults had two or more.⁵¹ Weiss et al, used survey weights and examined deeper combinations of chronic disease, but only in five conditions using 1999-2004 National Health and Nutrition Examination Survey (NHANES) data.²⁴

Several studies have been conducted in specific subpopulations of the U.S. using ARM or similar methods to examine combinations of multimorbidity. Koroukian et al. used ARM to identify combinations of multimorbidity associated with high expenditures among Medicare enrollees. Ho et al. used ARM to identify high-risk comorbidity combinations for patients undergoing emergency general surgery using the Nationwide Inpatient Sample. Uniones et al. (2016) and Quinones et al. (2019) examined diabetes comorbidities and racial disparities in multimorbidity, respectively using the Health & Retirement Study. Uniones et al. (2022) examined combinations associated of multimorbidity among patients seeking care at community

health centers.⁵³ Steinman et al. examined combinations of multimorbidity impacting older veterans using data form the Veterans Affairs health system.²¹ 277

Comparable studies have been conducted internationally outside the U.S., including a study using the Korea Health Panel which found an overall multimorbidity rate of 34.8% in South Korea,⁵⁴ and a study using Beijing medical claims data in China, which found a higher rate of multimorbidity than our study (51.6% in mid-life adults and 81.3% in older adults). This is probably due to including more conditions. Zemekidun et al. applied cluster analysis and ARM to the UK biobank to identify combinations of multimorbidity.⁵⁵ Britt et al. examined prevalence and patterns of multimorbidity in patient-reported surveys in Australia across nine morbidity domains.⁵⁶ The most common combination was arthritis/chronic back pain + vascular disease (15% of population). Nicholson et al. developed a cluster analysis tool to identify common combinations and sequences in Canada using an approach that seems similar to association rule mining.32

Strengths

276

278 279

280

281 282

283

284

285 286

287

288

289

298

299

300

301

302 303

304

305

306 307

308

309

310

311 312

313

314

- The data mining allowed a more comprehensive identification of high frequency multimorbidity 290 combinations than previous efforts. 23,24 This study uses a national sample, representative of the 291 U.S. population. The MEPS database is also unique among national surveys in that its open-292 293 ended condition enumeration approach (rather than a fixed set of questions) allows for a more 294 comprehensive capture of different chronic conditions, compared to other national 295 surveys. 17,23,24 MEPS covers all payers (even uninsured) and has data on services from all 296 providers, which is an advantage over big data sources like claims data and electronic health 297 records, respectively.
 - Association rule mining allows for the identification of highly prevalent combinations in a quick and computationally efficient manner, while filtering out combinations that have no observations or are sparse. While our study only focused on combinations occurring in over 1 million adults, the method could also be used to identify higher order combinations by setting a lower prevalence thresholds. Association rule mining is still relatively uncommon in clinical and epidemiological studies. The method could be applied to other areas of research, for example identifying high-risk combinations of risk factors associated with mortality, 38 social determinant of health indicators associated with disparities, ⁵⁷ or prescription drug combinations associated with adverse drug events.⁵⁸ To our knowledge, this is the first study to combine complex survey analysis with association rule mining to yield national estimates of combinations of variables.

Limitations

MEPS provides accurate estimates of treated prevalence for chronic disease, but this is likely lower than the underlying population prevalence for some conditions, especially those that are less salient.³⁰ On the other hand, the focus on treated conditions represent those for which care decisions between multiple conditions may conflict. The MEPS includes community-dwelling subjects only, meaning institutionalized persons such as nursing home and assisted living residents are excluded. Estimates of total expenditures are typically lower than what is

estimated from the National Health Expenditure Accounts (NHEA), because the MEPS does not 315 include these institutionalized populations.⁵⁹ ICD-10 codes were classified into 20 primary-care 316 relevant conditions using an established algorithm, but other classification systems may result in 317 different combinations and prevalence estimates.³¹ This algorithm was chosen over others 318 319

because it was originally designed for use on self-reported conditions, and that it could be

320 applied with the 3-digit ICD-10 codes available in MEPS. Many other algorithms require the use

of fully-specified ICD-10 codes and/or were designed for use in administrative data, including

Elixhauser comorbidities, 60 Deyo-Charlson Comorbidity Index, 61,62 Clinical Classification

Software, 63 and Phecodes. 64 Consensus on which conditions to include in measures of

multimorbidity has not been established, and is a problem that continues to plague the field.⁶⁵

- This study used the most recent data (2016-2019) available at the time; therefore, the impact of 325
- 326 the COVID-19 pandemic was not captured in these results. As comorbidities were among the
- 327 greatest risk factors of COVID-related death, excess mortality in people with multimorbidity
- could have lowered population prevalence rates. 66-68 However, there is growing evidence of 328
- increases in prevalence of certain post-Covid conditions (i.e. long COVID) including respiratory 329
- 330 problems, diabetes, heart conditions, neurological conditions, migraines, and mental health
- conditions. 69-73 Understanding the scale and impact of post-COVID conditions is an on-going 331
- area of investigation in the scientific community. 332

Conclusion

321

322

323

324

333

339

340

345

346

350

351

- 334 This cross-sectional analysis of a nationally-representative survey showed that certain
- 335 multimorbidity combinations of disease are quite common in the US, occurring in one million or
- 336 more adults. The combinations reported here could be prioritized for evidence-based research
- 337 and integration into practice guidelines, especially those most associated with poor health and
- 338 high medical costs.

DATA AVAILABILITY STATEMENT

- 341 This study uses openly available data from the Medical Expenditure Panel Survey. Available at:
- 342 https://www.meps.ahrq.gov/mepsweb/data stats/download data files.jsp. Requests to access
- 343 the processed dataset used in analysis should contact the corresponding author. Project code is
- 344 posted on the author's GitHub: https://github.com/nickschiltz/multimorbidity-prevalence

ETHICS STATEMENT

- 347 This study uses only publicly available deidentified datasets. The Case Western Reserve
- 348 University Institutional Review Board reviewed the protocol for this study and deemed it to be
- exempt under U.S. federal law. 349

AUTHOR CONTRIBUTIONS

NKS is the sole author, had full access to the data, and takes responsibility for the integrity of the data and the accuracy of the data analysis, and the entirety of the manuscript. NKS contributions include conceptualization, design of the study, statistical analysis, interpreting the data, and writing and revising the manuscript.

FUNDING

This project was supported in part by NIH/NCATS CTSA KL2TR002547. Its contents are solely the responsibility of the author and do not necessarily represent the official views of the NIH.

CONFLICTS OF INTEREST

The author of this report has no conflicts of interest to disclose.

ACKNOWLEDGEMENTS

The author would like to thank Obada Farhan, MS (Case Western Reserve University) and R. Henry Olaisen for their roles in writing some of the R code used in the analysis, and Kurt Stange, MD, PhD for his mentorship on the career development award that supported this work.

REFERENCES

372

- Buttorff C, Ruder T, Bauman M. Multiple Chronic Conditions in the United States. RAND
 Corporation; 2017. Accessed October 5, 2019. https://www.rand.org/pubs/tools/TL221.html
- Fortin M, Bravo G, Hudon C, et al. Relationship between multimorbidity and health-related quality of life of patients in primary care. *Qual Life Res Int J Qual Life Asp Treat Care Rehabil.* 2006;15(1):83-91. doi:10.1007/s11136-005-8661-z
- 378 3. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA.
 379 Causes and consequences of comorbidity: a review. *J Clin Epidemiol*. 2001;54(7):661-674.
 380 doi:10.1016/s0895-4356(00)00363-2
- Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. *Arch Intern Med.* 2002;162(20):2269-2276.
 doi:10.1001/archinte.162.20.2269
- Koroukian SM, Schiltz N, Warner DF, et al. Combinations of Chronic Conditions,
 Functional Limitations, and Geriatric Syndromes that Predict Health Outcomes. *J Gen Intern Med.* 2016;31(6):630-637. doi:10.1007/s11606-016-3590-9
- 387 6. Schiltz NK, Warner DF, Sun J, et al. Identifying Specific Combinations of Multimorbidity 388 that Contribute to Health Care Resource Utilization: An Analytic Approach. *Med Care*. 389 2017;55(3):276-284. doi:10.1097/MLR.000000000000660
- Buffel du Vaure C, Ravaud P, Baron G, Barnes C, Gilberg S, Boutron I. Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. *BMJ Open.* 2016;6(3):e010119.
 doi:10.1136/bmjopen-2015-010119
- 394 8. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. *N Engl J Med.* 2004;351(27):2870-2874. 396 doi:10.1056/NEJMsb042458
- Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical Practice Guidelines and
 Quality of Care for Older Patients With Multiple Comorbid Diseases: Implications for Pay
 for Performance. *JAMA*. 2005;294(6):716-724. doi:10.1001/jama.294.6.716
- 400 10. Boyd CM, Kent DM. Evidence-Based Medicine and the Hard Problem of Multimorbidity. *J* 401 *Gen Intern Med.* 2014;29(4):552-553. doi:10.1007/s11606-013-2658-z
- 402 11. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. *Nat Med.* 2019;25(12):1822-1832. doi:10.1038/s41591-019-0675-0
- 404 12. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and 405 other disorders. *Nat Rev Neurosci.* 2011;12(12):723-738. doi:10.1038/nrn3114
- James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence,
 and years lived with disability for 354 diseases and injuries for 195 countries and
 territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.

409 The Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7

410 14. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. *Ann Fam*

412 *Med.* 2012;10(2):142-151. doi:10.1370/afm.1337

413 15. Salive ME. Multimorbidity in Older Adults. *Epidemiol Rev.* 2013;35(1):75-83.

- 414 doi:10.1093/epirev/mxs009
- 415 16. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health
- 416 consequences, and implications for quality, care management, and costs. *J Gen Intern*
- 417 *Med.* 2007;22 Suppl 3:391-395. doi:10.1007/s11606-007-0322-1
- 418 17. Quiñones AR, Markwardt S, Botoseneanu A. Multimorbidity Combinations and Disability in
- 419 Older Adults. *J Gerontol A Biol Sci Med Sci.* 2016;71(6):823-830.
- 420 doi:10.1093/gerona/glw035
- 421 18. Quiñones AR, Markwardt S, Thielke S, Rostant O, Vásquez E, Botoseneanu A.
- 422 Prospective Disability in Different Combinations of Somatic and Mental Multimorbidity. J
- 423 Gerontol Ser A. 2018;73(2):204-210. doi:10.1093/gerona/glx100
- 19. Valderas JM, Gangannagaripalli J, Nolte E, et al. Quality of care assessment for people
- with multimorbidity. *J Intern Med.* 2019;285(3):289-300. doi:10.1111/joim.12881
- 426 20. Lochner KA, Cox CS. Prevalence of multiple chronic conditions among Medicare
- beneficiaries, United States, 2010. Prev Chronic Dis. 2013;10:E61.
- 428 doi:10.5888/pcd10.120137
- 429 21. Steinman MA, Lee SJ, Boscardin WJ, et al. Patterns of Multimorbidity in Elderly Veterans.
- 430 J Am Geriatr Soc. 2012;60(10):1872-1880. doi:10.1111/j.1532-5415.2012.04158.x
- 431 22. Garin N, Koyanagi A, Chatterji S, et al. Global Multimorbidity Patterns: A Cross-Sectional,
- 432 Population-Based, Multi-Country Study. J Gerontol A Biol Sci Med Sci. 2016;71(2):205-
- 433 214. doi:10.1093/gerona/glv128
- 434 23. Ward BW. Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From
- the National Health Interview Survey, 2010. *Prev Chronic Dis.* 2013;10.
- 436 doi:10.5888/pcd10.120203
- 437 24. Weiss CO, Boyd CM, Yu Q, Wolff JL, Leff B. Patterns of Prevalent Major Chronic Disease
- 438 Among Older Adults in the United States. *JAMA*. 2007;298(10):1158-1162.
- 439 doi:10.1001/jama.298.10.1160-b
- 440 25. Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of Multimorbidity in a
- 441 Geographically Defined American Population: Patterns by Age, Sex, and Race/Ethnicity.
- 442 *Mayo Clin Proc.* 2014;89(10):1336-1349. doi:10.1016/j.mayocp.2014.07.010
- 443 26. Koroukian SM, Schiltz NK, Warner DF, et al. Multimorbidity: constellations of conditions
- 444 across subgroups of midlife and older individuals, and related Medicare expenditures. J
- 445 *Comorbidity.* 2017;7(1):33-43. doi:10.15256/joc.2017.7.91

- Cohen J. Methodology Report #1: Design and Methods of the Medical Expenditure Panel
 Survey Household Component. Agency for Health Care Policy and Research; 1997.
- Accessed October 26, 2014. http://meps.ahrq.gov/data_files/publications/mr1/mr1.shtml
- 449 28. Agency for Healthcare Research and Quality. MEPS HC 2036: 1996 2015 Pooled 450 Estimation File. Accessed May 25, 2022.
- 451 https://meps.ahrq.gov/data_stats/download_data/pufs/h36/h36u15doc.shtml
- 452 29. Sommers J. An Examination of State Estimates Using Multiple Years of Data from the 453 Medical Expenditure Panel Survey, Household Component. Agency for Healthcare
- 454 Research & Quality; 2006. Accessed October 6, 2022.
- 455 https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.568.2822&rep=rep1&type=pdf
- 456 30. Machlin S, Cohen J, Elixhauser A, Beauregard K, Steiner C. Sensitivity of Household Reported Medical Conditions in the Medical Expenditure Panel Survey: *Med Care*.
- 458 2009;47(6):618-625. doi:10.1097/MLR.0b013e318195fa79
- 459 31. Fortin M, Almirall J, Nicholson K. Development of a Research Tool to Document Self-460 Reported Chronic Conditions in Primary Care. *J Comorbidity*. 2017;7(1):117-123. 461 doi:10.15256/joc.2017.7.122
- 462 32. Nicholson K, Bauer M, Terry AL, Fortin M, Williamson T, Thind A. The multimorbidity cluster analysis tool: identifying combinations and permutations of multiple chronic
- diseases using a record-level computational analysis. *BMJ Health Care Inform.*
- 465 2017;24(4):339-343. doi:10.14236/jhi.v24i4.962
- 466 33. Nicholson K, Terry AL, Fortin M, Williamson T, Bauer M, Thind A. Prevalence,
- characteristics, and patterns of patients with multimorbidity in primary care: a retrospective
- 468 cohort analysis in Canada. *Br J Gen Pract*. 2019;69(686):e647-e656.
- 469 doi:10.3399/bjgp19X704657
- 470 34. Machlin, S, Dougherty D. Overview of Methodology for Imputing Missing Expenditure Data in the Medical Expenditure Panel Survey. Published online March 2007.
- http://www.meps.ahrg.gov/mepsweb/data_files/publications/ mr19/mr19.pdf
- 473 35. Dunn A, Grosse SD, Zuvekas SH. Adjusting Health Expenditures for Inflation: A Review of
- 474 Measures for Health Services Research in the United States. *Health Serv Res*.
- 475 2018;53(1):175-196. doi:10.1111/1475-6773.12612
- 476 36. Agrawal R, Srikant R. Fast algorithms for mining association rules. In: *Proc. of 20th Intl.* 477 *Conf. on VLDB.*; 1994:487-499.
- 478 37. Lumley T. Complex Surveys: A Guide to Analysis Using R. Wiley; 2010.
- 479 38. Ho VP, Schiltz NK, Reimer AP, Madigan EA, Koroukian SM, High-Risk Comorbidity
- 480 Combinations in Older Patients Undergoing Emergency General Surgery: COMORBIDITY
- 481 COMBINATIONS IN EMERGENCY SURGERY. J Am Geriatr Soc. 2019;67(3):503-510.
- 482 doi:10.1111/jgs.15682

483 39. Bayardo RJ, Agrawal R, Gunopulos D. Constraint-based rule mining in large, dense 484

databases. In: Proceedings 15th International Conference on Data Engineering (Cat.

- 485 No.99CB36337). IEEE; 1999:188-197. doi:10.1109/ICDE.1999.754924
- 486 40. Hahsler M, Buchta C, Gruen B, Hornik K, Borgelt C. arules: Mining Association Rules and Frequent Itemsets. Published online October 2, 2016. Accessed January 31, 2017. 487
- 488 https://cran.r-project.org/web/packages/arules/index.html
- 489 41. Lumley T. Analysis of complex survey samples. J Stat Softw. 2004;9(1):1-19.
- 490 42. Lithell H. Hypertension and Hyperlipidemia: A Review. Am J Hypertens. 491 1993;6(11 Pt 2):303S-308S. doi:10.1093/ajh/6.11.303S
- 492 43. Muth C, Blom JW, Smith SM, et al. Evidence supporting the best clinical management of 493 patients with multimorbidity and polypharmacy: a systematic guideline review and expert 494 consensus. J Intern Med. 2019;285(3):272-288. doi:10.1111/joim.12842
- 44. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among 495 496 adults seen in family practice. Ann Fam Med. 2005;3(3):223-228. doi:10.1370/afm.272
- 497 45. Mokraoui NM, Haggerty J, Almirall J, Fortin M. Prevalence of self-reported multimorbidity in 498 the general population and in primary care practices: a cross-sectional study. BMC Res 499 Notes. 2016;9:314. doi:10.1186/s13104-016-2121-4
- 500 Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in 501 patients with multimorbidity in primary care and community settings. Cochrane Database 502 Syst Rev. 2021;1:CD006560. doi:10.1002/14651858.CD006560.pub4
- 503 47. Zeiss AM, Steffen AM. Interdisciplinary health care teams: The basic unit of geriatric care. 504 In: The Practical Handbook of Clinical Gerontology. Sage Publications, Inc; 1996:423-450.
- 505 Mate KS, Berman A, Laderman M, Kabcenell A, Fulmer T. Creating Age-Friendly Health 506 Systems – A vision for better care of older adults. *Healthcare*. 2018;6(1):4-6. 507 doi:10.1016/j.hjdsi.2017.05.005
- 508 49. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START 509 criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 510 2015;44(2):213-218. doi:10.1093/ageing/afu145
- 511 50. 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American 512 Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate
- 513 Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694.
- 514 doi:10.1111/jgs.15767
- 515 51. Boersma P, Black LI, Ward BW. Prevalence of Multiple Chronic Conditions Among US 516 Adults, 2018. Prev Chronic Dis. 2020;17:E106. doi:10.5888/pcd17.200130
- 517 Quiñones AR, Botoseneanu A, Markwardt S, et al. Racial/ethnic differences in 518 multimorbidity development and chronic disease accumulation for middle-aged adults.
- 519 PloS One. 2019;14(6):e0218462. doi:10.1371/journal.pone.0218462

520 53. Quiñones AR, Valenzuela SH, Huguet N, et al. Prevalent Multimorbidity Combinations
 521 Among Middle-Aged and Older Adults Seen in Community Health Centers. *J Gen Intern* 522 *Med.* Published online January 28, 2022. doi:10.1007/s11606-021-07198-2

- 523 54. Lee Y, Kim H, Jeong H, Noh Y. Patterns of Multimorbidity in Adults: An Association Rules
 524 Analysis Using the Korea Health Panel. *Int J Environ Res Public Health*. 2020;17(8):2618.
 525 doi:10.3390/ijerph17082618
- 526 55. Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of Multimorbidity in
 527 Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. *Mayo Clin Proc*.
 528 2018;93(7):857-866. doi:10.1016/j.mayocp.2018.02.012
- 56. Britt HC, Harrison CM, Miller GC, Knox SA. Prevalence and patterns of multimorbidity in Australia. *Med J Aust.* 2008;189(2):72-77. doi:10.5694/j.1326-5377.2008.tb01919.x
- 531 57. Schiltz NK, Chagin K, Sehgal AR. Clustering of Social Determinants of Health Among
 532 Patients. *J Prim Care Community Health*. 2022;13:21501319221113544.
 533 doi:10.1177/21501319221113543
- 534 58. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel Data Mining 535 Methodologies for Adverse Drug Event Discovery and Analysis. *Clin Pharmacol Ther*. 536 2012;91(6):1010-1021. doi:10.1038/clpt.2012.50
- 537 59. Bernard D, Cowan C, Selden T, Cai L, Catlin A, Heffler S. Reconciling medical expenditure 538 estimates from the MEPS and NHEA, 2007. *Medicare Medicaid Res Rev*. 539 2012;2(4):mmrr.002.04.a09. doi:10.5600/mmrr.002.04.a09
- 540 60. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care*. 1998;36(1):8-27.
- 542 61. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-543 CM administrative databases. *J Clin Epidemiol*. 1992;45(6):613-619. doi:10.1016/0895-544 4356(92)90133-8
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J Chronic Dis*.
 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8
- Elixhauser A, Steiner C, Palmer L. Clinical Classification Software (CCS), 2012. U.S.
 Agency for Healthcare Research & Quality.; 2012. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
- 551 64. Wei WQ, Bastarache LA, Carroll RJ, et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. *PLOS ONE*. 2017;12(7):e0175508. doi:10.1371/journal.pone.0175508
- 554 65. Stirland LE, González-Saavedra L, Mullin DS, Ritchie CW, Muniz-Terrera G, Russ TC.
 555 Measuring multimorbidity beyond counting diseases: systematic review of community and
 556 population studies and guide to index choice. *BMJ*. 2020;368:m160. doi:10.1136/bmj.m160

- 557 66. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, 558 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City 559 Area. *JAMA*. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
- 560 67. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in
 561 Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. *Arch Acad Emerg Med.* 2020;8(1):e35.
- 563 68. Chudasama YV, Zaccardi F, Gillies CL, et al. Patterns of multimorbidity and risk of severe
 564 SARS-CoV-2 infection: an observational study in the U.K. *BMC Infect Dis.* 2021;21(1):908.
 565 doi:10.1186/s12879-021-06600-y
- Hernandez-Romieu AC, Carton TW, Saydah S, et al. Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2. *JAMA Netw Open*.
 2022;5(2):e2147053. doi:10.1001/jamanetworkopen.2021.47053
- 70. Wanga V. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 United States,
 571 January 2020–April 2021. MMWR Morb Mortal Wkly Rep. 2021;70.
 572 doi:10.15585/mmwr.mm7036a1
- 573 71. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study.
 574 Lancet Diabetes Endocrinol. 2022;10(5):311-321. doi:10.1016/S2213-8587(22)00044-4
- 575 72. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med.* 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3
- 577 73. Shanley JE, Valenciano AF, Timmons G, et al. Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms. *Ann Clin Transl Neurol*. 2022;9(7):995-579 1010. doi:10.1002/acn3.51578

FIGURE CAPTIONS

Figure 1: Highly prevalent specific combinations of multimorbidity and associated cost and perceived poor health. The figure shows combinations of conditions with an estimated prevalence of 5 million or more adults in the United States. Data source: the 2016-2019 Medical Expenditure Panel Survey (MEPS). Weighted estimates and 95% confidence intervals were calculated by applying population weights using Taylor-series methods (i.e. complex survey methods) to account for the complex sampling design of the MEPS. Weighted estimates have been annualized by taking the average over the four-year study period. X-axes for prevalence and cost are on the logarithmic scale. Results are sorted by prevalence. Cost is measured as total annual medical expenditures in 2019 US Dollars, and perceived health is an answer of "fair" or "poor" on a 5-point question asking respondents to rank their overall health.


Figure 2: Specific combinations of multimorbidity ranked highest in terms of average cost or perceived poor health. The figure shows the specific combinations of multimorbidity that ranked in the top 20 in terms of highest average cost per person or top 20 highest percentage with self-reported poor health. A total of 28 conditions met either criterion, with 12 meeting both. Data source: 2016-2019 Medical Expenditure Panel Survey (MEPS). Weighted estimates and 95% confidence intervals were calculated by applying population weights using Taylor-series methods (i.e. complex survey methods) to account for the complex sampling design of the MEPS. Weighted estimates have been annualized by taking the average over the four-year study period. Adjusted odds ratios were calculated using log-binomial models adjusting for age, race, and sex, and Taylor-series methods for standard errors. X-axes are on the logarithmic scale, and results are sorted by prevalence.

Figure 3: Top ten most prevalent specific combinations of multimorbidity by sex and associated cost and perceived poor health. The figure shows the top ten combinations of conditions as ranked by prevalence by sex among adults in the United States. Panel A shows data on males, and Panel B shows data on females. Data source: the 2016-2019 Medical Expenditure Panel Survey (MEPS). Weighted estimates and 95% confidence intervals were calculated by applying population weights using Taylor-series methods (i.e. complex survey methods) to account for the complex sampling design of the MEPS. Weighted estimates have been annualized by taking the average over the four-year study period. X-axes for prevalence and cost are on the logarithmic scale. Results are sorted by prevalence. Cost is measured as total annual medical expenditures in 2019 US Dollars, and perceived health is an answer of "fair" or "poor" on a 5-point question asking respondents to rank their overall health.

Table 1: Number of Chronic Conditions Treated among U.S. Adults by Population Characteristics

Table 1 caption: Survey-weighted estimates from pooling the 2016-2019 Medical Expenditure Panel Survey. Weighted estimates have been annualized by taking the average over the four year study period. Row percentages are reported under each count of conditions column. Medical expenditures are reported in 2019 US Dollars (USD).

Variable	No. in unweighted sample	Weighted No. of Adults	0 chronic conditions, Row %	1+ chronic conditions, Row %	2+ chronic conditions, Row %	3+ chronic conditions, Row %	4+ chronic conditions, Row %
Age Group							
18 - 39	17,745	94,573,000	73.9%	26.1%	7.9%	2.7%	0.9%
40 - 64	19,776	102,614,000	41.1%	58.9%	35.5%	20.0%	10.6%
65 and older	9,311	52,034,000	11.6%	88.4%	73.0%	54.9%	36.1%
Sex							
Male	21,671	120,330,000	52.4%	47.6%	29.9%	18.8%	10.7%
Female	25,161	128,891,000	42.7%	57.3%	35.7%	22.5%	13.7%
Race / Ethnicity							
Hispanic	12,841	40,533,000	63.3%	36.7%	19.5%	11.6%	6.2%
Non-Hispanic White only	21,164	156,551,000	40.7%	59.3%	38.4%	24.5%	14.9%
Non-Hispanic Black only	8,113	29,523,000	53.0%	47.0%	28.9%	18.0%	10.1%
Non-Hispanic Asian only	3,355	15,133,000	62.4%	37.6%	20.0%	11.3%	5.4%
Other or Multiple Race	1,359	7,481,000	47.8%	52.2%	32.7%	21.0%	12.8%
Self-rated Poor Health	7,201	31,085,000	19.0%	81.0%	64.6%	48.8%	34.3%
Per capita medical expenditures			\$322	\$4,176	\$6,208	\$8,177	\$10,821
in 2019 USD (Median, IQR)			(\$0 – \$1,382)	(\$1,523 – \$11,067)	(\$2,558 – \$14,858)	(\$3,610 – \$18,756)	(\$5,045 – \$23,712)
Per capita out-of-pocket medical expenditures in 2019 USD (Median, IQR)			\$30 (\$0 – \$287)	\$11,007) \$542 (\$167 - \$1,401)	\$695 (\$243 - \$1,681)	\$808 (\$292 - \$1,865)	\$903 (\$333 - \$2,080)






Figure 3

Panel A: Males

